Navigation Links
Glenmark Wins Two Prestigious Global Recognitions at SCRIP Awards 2011
Date:11/4/2011

MUMBAI, India, November 4, 2011 /PRNewswire/ --

SCRIP, a leading global pharmaceutical and biotech news publication, honoured Glenmark with two global recognitions, for its business excellence and innovative R & D capabilities. At a glittering ceremony in London which was attended by the Who's Who of the world pharmaceutical industry on November 3; Glenmark was presented with 'Best Company in Emerging Markets' & 'Best Overall Pipeline' recognitions for the year 2011.

"On behalf of our 8000 employees worldwide, we are honoured to receive two prestigious distinctions from a reputed organisation like Informa Healthcare, which hosts the SCRIP Awards," said Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals Limited, who received the awards on behalf of the company.  "We are specially delighted at having bagged the 'Best Overall Pipeline' distinction which is a testimony of our world-class R&D capabilities and an enormous tribute to all our research staff around the world who have committed themselves over many years to the development of our innovative pipeline," he added.

For SCRIP Awards 2011, Glenmark was the only company worldwide to be shortlisted under four categories. 'Executive of the Year - Glenn Saldanha' and 'Licensing Deal of the Year - GBR 500' were the other 2 categories, where Glenmark was nominated for this year's awards.

While announcing the nominations for Glenmark; SCRIP magazine commented:

  • "Glenmark is a leader among the emerging market companies in drug discovery and development and most of its active substances in the pipeline are first-in-Class." *1
  • "Glenmark's achievements over the year included a major deal with Sanofi in Crohn's disease, completing Phase III trials of its first novel product, crofelemer and demonstrated higher sales and profit growth."*2

* 1 SCRIP magazine issue dated Sep 23, 2011  * 2 SCRIP magazine issue dated Sep 16, 2011

About Glenmark

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India.  It is a leading player in the discovery of new molecules, both NCEs (new chemical entity) and NBEs (new biological entity).  Glenmark has eight molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis, IBD, etc.] and Pain [neuropathic pain and inflammatory pain].


'/>"/>
SOURCE Glenmark Pharmaceuticals Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pars Development and Marketing Partner, Glenmark, Enters Into A Settlement Agreement With Merck To Settle Patent Litigation Over Generic ZETIA(R)
2. Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. COPAN WASP® Lands at Prestigious Boston Medical Center
5. NxStage Board Member Dr. Barry M. Straube Honored with Prestigious Award from the American Association of Kidney Patients
6. Portrait Plasma Skin Regeneration Resurfaces at Prestigious Symposium
7. ITelagen Named to Prestigious 2011 Inc. 5000 List of Fastest-Growing Companies
8. Upsher-Smith Receives Prestigious DIANA Award for Third Year in a Row
9. Cambridge Temperature Concepts Wins Prestigious Award From the Wireless-Life Sciences Alliance for Fertility Monitor DuoFertility
10. Luminex Corporation Wins Prestigious Medical Design Excellence Award
11. Xenon Chief Scientific Officer, Dr. Michael Hayden Receives Prestigious Award for Leadership in Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... SAN DIEGO , Jan. 18, 2017 /PRNewswire/ ... and innovative products to treat a variety of ... its lead compound DMT210, in a Phase 2 ... specifically developed to downregulate the proinflammatory cytokines in ... seen in acne rosacea. This ...
(Date:1/18/2017)... January 18, 2017 The report " Automated Breast Ultrasound ... Volume Scanner), By End User (Hospitals, Diagnostic Imaging Centers), Industry Analysis Report, Regional ... Argentina , Germany , UK, France ... Russia , China , Japan ... Thailand , Saudi Arabia , UAE, South ...
(Date:1/18/2017)... , Jan. 18, 2017  Tarix Orphan LLC ... has granted a Rare Pediatric Disease (RPD) designation for ... Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin ... and treatment is limited to supportive care. ... Orphan Drug Designation previously granted by the FDA in ...
Breaking Medicine Technology:
(Date:1/18/2017)... , ... January 18, 2017 , ... ... announce that their Vice President of Franchise Development, Paula Turner Pizarro, was recently ... business program, which features the insights of top business leaders from across the ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... solutions for drugs, biologics and consumer health products, today announced that Mr. Michael ... the upcoming WCBP Conference, to be held at the Mayflower Hotel, Washington DC, ...
(Date:1/18/2017)... ... ... Floundering on New Year’s resolutions? Need an excuse to get back on ... U.S. Apple Association agrees and recommends starting each day with apples, a habit ... disease. , The U.S. Apple Association – which represents apple growers and producers nationwide ...
(Date:1/17/2017)... ... ... For breast cancer clinicians and researchers who were unable to attend the ... review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual Best ... February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO from ...
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic Research will demonstrate ... Music Merchants (NAMM) winter trade show, Booth #2876, at the Anaheim Convention Center ... been the gold standard for high-definition, in-ear earphones. This classic earphone has been ...
Breaking Medicine News(10 mins):